

oncogene. The tumors were characterized for molecular characteristics, histologic phenotypes and angiogenesis, and expended in vivo for multiple in vivo pharmacological studies. Like human tumor populations, this population based tumor model exhibited significant inter-tumor variation in gene expression and tumor microvasculature. We therefore deployed the model for drug response biomarker discovery.

Results: Treatment of a subset of the tumors with the potent selective VEGFR inhibitor tivozanib which is currently in phase 3 clinical trial for kidney cancer revealed significant variation in response. Pharmacogenomic analysis using a novel coherence based bioinformatics approach revealed the association of a specific biological phenotype comprising tumor myeloid infiltration with drug resistance. A multi-gene signature derived from the biological phenotype has been used to query genetic data of human tumor populations. The result suggests that the drug resistance phenotype is represented in a subset of all solid tumor types examined but frequencies vary. We have subsequently developed a single, semi-quantitative immunohistochemistry (IHC) marker that represents the drug resistance phenotype. In a retrospective analysis of RCC patients that have received tivozanib monotherapy a significant correlation between the IHC biomarker and drug response (by RECIST) has been observed.

Conclusion: These results provide a promising candidate predictive biomarker for tivozanib activity in patients and indicate the utility of tumor population based models for biomarker discovery.

PP 55

Serum levels of the extracellular domain of HER-2 receptor in osteosarcoma patients

I. LUGOWSKA, W. Woźniak, K. Szamotulska, J. Ambroszkiewicz, J. Gajewska, P. Rutkowski. *Maria Skłodowska Curie Memorial Cancer Centre – Institute of Oncology, Warsaw, Poland*

Background: The prognostic role of HER-2 expression in osteosarcoma is controversial. The aim of the study was to assess a clinical value of the serum extracellular domain of HER-2 receptor (ECD/HER-2) level and its correlation with disease progression in patients with osteosarcoma.

Materials and Methods: 33 patients (aged 6–18 years, median 15 years) with primary osteosarcoma were analyzed; 13 were metastatic at presentation. Follow up period was 12–44 months; median 22 months. ECD/HER-2 levels were analyzed by ELISA method four times: at the time of diagnosis (1), before surgery of primary site (2), after surgery (3) and at the end of treatment 6–9 month since diagnosis (4). In 12 patients, tumor biopsy samples were available for assessment of the immunohistochemical HER-2 expression. The disease progression was confirmed by the CT scan and bone scan. The poor result of ECD/HER-2 value was calculated as higher than 5.5 ng/mL and/or elevated more than +1 ng/mL.

Results: Disease progression was observed in 10 patients, 7 of them died. 8/10 patient who progressed during treatment, had elevated ECD/HER-2 in serum. In 19/23 patient with SD/PR decreasing levels of ECD/HER-2 was observed; $P=0.001$. 6/7 patients who died had the ECD/HER-2 elevated during treatment or at the end of treatment. There was no relationship between ECD/HER-2 serum level and HER-2 expression in biopsy samples. Immunohistochemical expression of HER-2 did not correlate with treatment results.

Conclusion: This pilot study shows the possible clinical value of ECD/HER-2 assessment in serum of patients with osteosarcoma.

PP 68

Cytokines' profiles to predict chemotherapy outcome in castration resistant prostate cancer (CRPC)

K. MAHON, S. Breit, D. Brown, M. Molloy, G. Marx, M. Boyer, M. Stockler, S. Henshall, R. Sutherland, L. Horvath. *Sydney Cancer Centre, Royal Prince Alfred Hospital, Newtown, Australia*

Background: Chemotherapy improves symptoms and survival in advanced CRPC, however, around 50% of patients have chemoresistant disease. Early markers of chemoresistance will allow cessation of ineffective therapy and avoid toxicity. While MIC-1 and IL-6 may be markers of response, comprehensive cytokine evaluation has not been performed. This study examined whether early changes in cytokine levels can predict chemoresistance and clinical outcome.

Materials and Methods: Plasma/serum samples pre and post cycle 1 chemotherapy were collected from 59 men with metastatic CRPC (55 docetaxel, 7 mitoxantrone). Levels of 27 cytokines were measured using a bead-based immunoassay. MIC-1 levels were measured by ELISA. Patients were grouped as clinical responders (PR + SD) and non-responders (PD) based on PSA response criteria (PD >25% PSA increase over treatment course if no PSA response). The associations between cytokine levels, response groups and overall survival (OS) were assessed by non-parametric tests and Cox regression survival analysis.

Results: After one cycle of chemotherapy, non-responders had significantly greater increases in 10 cytokines from baseline compared with those who responded to treatment (MIC-1 $p=0.003$; IL1ra $p=0.004$; IL1b $p=0.01$; IL4 $p<0.001$; IL5 $p=0.041$; IL6 $p=0.003$; IL7 $p=0.009$; IL8 $p=0.017$; IL12 $p=0.004$; IFN gamma $p=0.001$). At a median survival of 15 months with 49 deaths, increases in IL8 (HR 2.4, 95% CI 1.1–5.0; $p=0.02$) and IFN gamma (HR 2.6, 95% CI 1.3–5.2; $p=0.009$) levels by more than 40% from baseline after one chemotherapy cycle were associated with poorer OS. Higher baseline MIC-1 levels also predicted shorter OS (HR 1.6, 95% CI 1.3–2.0; $p<0.0001$). In a multivariate model including presence of visceral metastases ($p=0.02$), Gleason score ($p=0.1$), baseline ALP ($p=0.2$), baseline Hb ($p=0.02$) and baseline PSA ($p=0.76$), baseline MIC-1 levels were an independent predictor of survival (HR 2.0, 95% CI 1.3–3.1; $p=0.002$).

Conclusion: Early changes in circulating levels of cytokines were associated with chemoresistance in men with CRPC. Additional associations between OS, baseline MIC-1 levels and changes in IL8 and IFN gamma levels suggest inflammation influences outcomes in men with CRPC treated with chemotherapy.

PP 96

NHERF1 in advanced colorectal cancer: its interaction with HIF-1 α and TWIST1 plays an important role in synchronous lymph node and liver metastases

A. Malfetone, C. Saponaro, R. Daprile, G. Simone, A. Paradiso, A. Mangia. *National Cancer Centre – Istituto Tumori "G. Paolo II" Bari, Bari, Italy*

Background: Colorectal cancer (CRC) is one of the major malignancies worldwide and recurrence and metastasis is the leading cause of death in CRC patients. Despite recent advances, characterization of new potential biomarker may be useful for the outcome prediction and fundamental to correct management of the disease. NHERF1, a potential candidate of clinical relevance for breast cancer, has been shown to be a new player in CRC progression, promoting Wnt signaling pathway by direct interaction with β -catenin. TWIST1, a basic helix-loop-helix transcription factor, is essential in mediating cancer metastasis through the epithelial-mesenchymal transition (EMT) and, recently, a new finding showed that TWIST1 is critical for hypoxia-mediated EMT. Aim of this study was to investigate the correlation among the expression of NHERF1, HIF-1 α , and TWIST1 in metastatic CRC.

Materials and Methods: We assayed NHERF1, HIF-1 α , and TWIST1 protein expressions by immunohistochemistry in 51 patients diagnosed with Stage IV CRC, whose distant non-tumoral tissues (DNT), primary tumor (T) and adjacent non-tumoral tissue (NT), lymph node (LnM) and liver metastases (LM) were available.

Results: A shift of NHERF1 from the apical membrane of DNT and NT, to cytoplasmic and nuclear compartments of T, LnM and LM was noticed. Cytoplasmic NHERF1 expression was statistically higher in T, LnM and LM than DNT and NT ($P<0.0001$). Nuclear NHERF1, such as HIF-1 α , was found significantly overexpressed in T and metastatic compartments compared to DNT ($P<0.0001$). TWIST1 is upregulated in tumor compared with normal tissue and protein expression was significantly higher in T than LnM and LM ($P<0.0001$). Spearman's rank test showed that nuclear NHERF1 was directly correlated to TWIST1 in T ($P=0.015$, $r=0.339$), and, a significant association between HIF-1 α and TWIST1 was also noticed in T ($P=0.016$, $r=0.365$).

Conclusion: These results indicate that NHERF1 expression results strongly related to the hypoxic microenvironment of metastatic CRC. Tumor progression and metastasis are mediated by a key signaling pathway involving nuclear NHERF1 together with HIF-1 α and TWIST1. Thus, we propose nuclear NHERF1 as a new diagnostic marker of advanced malignancy.

PP 11

Correlation between both serum osteopontin/osteonectin and bone remodelling parameters, inflammatory/metabolic variables and survival in metastatic cancer patients with tumors at different sites

G. Mantovani, C. Madeddu, G. Astara, L. Demurtas, G. Antoni, R. Serpe, V. Ruggiero. *Department of Medical Oncology, University of Cagliari, Italy, Cagliari, Italy*

Background: Osteopontin (OPN) is a secreted, integrin-binding phosphoprotein that has been correlated with tumor grade and stage and disease progression in several tumor types. High OPN levels have been clinically correlated with metastatic bone disease and bone resorption in cancer patients. The secreted protein, acidic and rich in cysteine (SPARC) is closely related to progression, invasion, angiogenesis and metastatic process of several malignant tumors. The aim of the study was to verify in a population of advanced cancer patients with tumors at different sites whether there is a correlation between circulating levels of OPN and SPARC

and clinical parameters (such as bone metastases, pain and quality of life), circulating bone remodeling (skeletal) parameters (alkaline phosphatase, C- and N-terminal fragments of type I collagen, osteocalcin, Vitamin D), inflammatory (IL-8 and TNF- α) and metabolic parameters (BMI, serum cholesterol and triglycerides).

Materials and Methods: From April 2010 to August 2010, we enrolled 33 metastatic cancer patients with tumors at different sites (M/F: 16/17, mean age 66 years): 17 patients with bone metastases, 16 with metastases not involving bone. Comparison between groups (controls vs cancer patients and cancer patients with vs without bone metastases) was performed by two-sided Student's t test. Correlation between OPN/SPARC and the other variables was performed by Spearman's correlation analysis.

Results: OPN and SPARC in cancer patients were significantly higher compared to controls but did not differ between patients with or without bone metastases. OPN showed a positive significant correlation with C and N terminal fragments of type I collagen ($r=0.390$ and $r=0.410$, $p=0.024$ for both), IL-8 ($r=0.390$, $p=0.034$) and a negative significant correlation with quality of life ($r=-0.400$, $p=0.025$) and BMI ($r=-0.300$, $p=0.046$). SPARC showed a positive significant correlation with BMI ($r=0.360$, $p=0.049$). Moreover, patients with 3 month survival (613.7 ± 229.2 ng/ml versus 195.8 ± 165 ng/ml, $p<0.001$).

Conclusion: The results of the present study show that high OPN levels are associated with poor survival in advanced cancer patients. Further studies are warranted to assess the role of OPN and SPARC to both monitor the effects of antineoplastic regimens and to assess them as potential targets of new treatment strategies.

PP 78

Role of mucin3 gene in intrinsic resistance to oxaliplatin

A. Martínez-Cardús, M. Sureda, J.L. Ramírez, A. Ginés, V. Ruíz de Porras, E. Bandrés, R. Malumbres, J. García-Foncillas, A. Abad, E. Martínez-Balibrea. *Fundació Institut d'investigació en ciències de la salut germans trias i pujol, Badalona, Spain*

Background: Although representing a milestone in the treatment of colorectal cancer (CRC) little is known about the mechanisms responsible for intrinsic resistance to oxaliplatin (OXA). We previously identified a set of genes whose expression was associated with intrinsic resistance to OXA in a panel of 14 CRC human cell lines. The aim of this work was to validate these findings in order to typify genes that could play a role as predictive markers of response to OXA-based treatment in CRC patients.

Materials and Methods: Candidate genes selected in a previous microarray analysis were validated by qRT-PCR with specific Taqman® Assays in 14 CRC cell lines comparing resistant ($R=IC_{50}>1 \mu M$) versus sensitive ($S=IC_{50}<1 \mu M$) groups. MTT assay was used to establish OXA, SN38, cisplatin and 5-fluorouracil sensitivity profiles. Genes showing statistically significant differences between both OXA sensitivity groups (U-Mann-Whitney) were considered as positively validated. MUC3A gene methylation status was analyzed by bisulphite treatment and PCR and correlated with mRNA expression results.

Results: Expression levels of 6 (MUC3, ABHD3, ERN1, JARID2, MPP6, TNFSF13) out of 16 genes were analysed by qRT-PCR. Only Mucin3 (MUC3A and B) was positively validated so that as compared with S cells, R cells expressed very low levels of MUC3 A and B (MUC3A mean 4.89 ± 2.91 and 0.97 ± 1.11 for S and R cells respectively, $p=0.01$; MUC3B mean 8.52 ± 5.49 and 1.47 ± 1.76 $p=0.008$). These data correlated with that obtained from the microarray (Rho-Spearman: $R=0.7$ $p=0.006$). This feature was OXA-specific since we did not observe cross-resistance with other drugs. We only observed a slightly correlation with gene methylation status in those cells with the lowest and highest values of MUC3A expression. In a small sample ($N=22$) of paraffin-embedded tumors from CRC patients treated with first line OXA-based chemotherapy MUC3A and B overexpression was associated with response to treatment (86.7% of responders had expression levels $>33\%$ percentile; Fisher's $p=0.12$; OR 3.75).

Conclusion: MUC3 A and B gene down-regulation is associated with intrinsic resistance to OXA both in vitro and in CRC patients. We could not demonstrate that regulation of MUC3A expression was dependent on methylation status. Although MUC3A and B are potential predictive markers of OXA response in CRC patients, functional studies are being conducted in order to elucidate the molecular mechanisms linking them with OXA intrinsic resistance and their potential role in CRC treatment selection.

PP 90

Glioma cell motility is modulated by CXCL12/CXCR4

D. Matias, A. Carmo, M.C. Lopes. *Centre for Neuroscience and Cell Biology, Leiria, Portugal*

Background: Gliomas are brain tumours that account for more than 50% of the tumors that arise within the central nervous system. They

are highly proliferative, angiogenic and locally very invasive. Despite the considerable advances in the knowledge of the mechanisms underlying the genetics, biology and clinical behavior, GBM pathogenesis is not completely understood and until now, there is not a therapeutic strategy to reduce the invasive and proliferative ability of the glioma cells. One of the therapeutic targets currently studied is the chemokine receptors. CXCR4 is the cell-surface receptor of CXCL12 also named stromal-derived stromal factor 1 and was associated to the tumorigenesis process in breast, prostate, kidney and brain. In order to understand the role of CXCL12/CXCR4 in gliomas we studied the survival and motility of glioma cells treated with AMD3100, an antagonist of the CXCR4.

Materials and Methods: We used the U-118 glioma cell line. The assays were performed in the presence and/or absence of CXCL12, and AMD3100. CXCR4 expression in glioma cells was evaluated by western blot and immunofluorescence. Cell survival was evaluated by flow cytometry. Cell migration study was performed using the scratch assay. Cytoskeleton organization was analysed using phalloidin.

Results: Our results showed that CXCR4 is expressed in the U-118 cell line. AMD3100, the CXCR4 antagonist, induces disruption of the cytoskeleton and a significant reduction of the migration and invasion ability of the glioma cells. The study of cell survival demonstrated that the inhibition of CXCR4 activity induces a decrease in cell survival.

Conclusion: Taking these results altogether it is possible to conclude that the activation of CXCR4 by CXCL12 promoted proliferation, survival, and migration of U-118 glioma cells, confirming that CXCR4/CXCL12 signaling pathway may contribute for the growth and invasive characteristics of GBM. In addition, it was demonstrated that the inhibition of the CXCR4/CXCL12 pathway by AMD3100, significantly inhibited the survival and motility of the glioma cells, indicating that the effect of AMD3100 should be confirmed in vivo in order to evaluate the potential of CXCR4 as a therapeutic target in the GBM treatment.

PP 74

A subtype representing activated ATM signalling in PTEN-null tumours

N. McCabe, S. Walker, N. Goffard, K. Wikstrom, C. Greenan, F. McDyer, L. Hill, S. Deharo, D.P. Harkin, R. Kennedy. *Almac Diagnostics, Craigavon, Northern Ireland*

Background: PTEN is frequently lost in cancer cells through genetic mutation or epigenetic silencing. Loss of PTEN function has been widely reported to cause up-regulation of the PI3K/AKT signalling pathway resulting in increased cell growth, proliferation and survival. More recently it has been reported that PTEN null cells demonstrate genomic instability through increased ROS and oxidative stress induced DNA damage. The aim of this study was to identify a biomarker for PTEN status in human cancers.

Materials and Methods: A metagene representing ATM activation was generated from public cell line data of AT fibroblasts treated with gamma-irradiation. This was used to perform hierarchical clustering analysis of a public DNA microarray profiling dataset with known PTEN IHC status. The metagene was validated in PTEN wildtype and null cancer cell lines.

Results: We found that PTEN null cells have elevated levels of ROS and furthermore activation of the DNA damage signalling kinase, ATM. In agreement with this, the ATM metagene signature correlated with PTEN mutation in breast cancer tumours. Scoring of PTEN wildtype and null cancer cell lines from various tissues using the metagene correlated with ATM activation and sensitivity to inhibition of ATM. Furthermore we show that inhibition of ATM caused DNA damage, cell cycle arrest and apoptosis in PTEN deficient cells suggesting a novel therapeutic strategy.

Conclusion: These observations suggest that ATM may represent a therapeutic target in PTEN deficient tumours and furthermore ATM activation may also be an important biomarker of PTEN mutation or loss.

PP 94

Polyamine Transport System (PTS) activity and hijacking in cancer cells: new option in Head and Neck tumors treatment with the polyamine-containing drug candidate F14512

S. Meignan, F. Mouawad, A. Dewitte, C. Bertheau, N. Wattez, E. Lartigau, D. Chevalier, C. Bailly, A. Lansiaux. *Inserm, Lille Cedex, France*

Background: The Polyamine Transport System, although not clearly identified at the molecular level in eukaryotic organisms, was found over activated in many types of cancer cells, such as leukemia, prostate, melanoma and NSCLC. Polyamines are implicated in many biological functions, and the need for polyamines in tumor cells, conveyed by the PTS, is crucial. New therapeutic strategies consist to use this transport system to deliver a cytotoxic agent specifically into cancer cells. Head and neck cancer remains the 6th common cancer with a very poor survival rate indicating the crucial need for new targeted strategies.